Literature DB >> 2579038

Isolation of simian retroviruses closely related to human T-cell leukemia virus by establishment of lymphoid cell lines from various non-human primates.

H Tsujimoto, A Komuro, K Iijima, J Miyamoto, K Ishikawa, M Hayami.   

Abstract

Simian retroviruses closely related to human T-cell leukemia virus (HTLV) were isolated by establishing virus-producing lymphoid cell lines from 7 species of non-human primates. By co-cultivation with human umbilical cord-blood cells and/or in the presence of interleukin-2, lymphoid cell lines were successfully established from the chimpanzee. African green monkey, pig-tailed macaque, red-faced macaque, Formosan monkey, Japanese monkey and bonnet monkey that had antibodies against HTLV antigens. These cell lines reacted with human sera of ATL patients and monoclonal antibodies against p19 and p24 of HTLV antigens. Cellular DNAs contained the provirus sequences homologous to HTLV-I by Southern blot hybridization. Moreover, they produced extracellular type-C virus particles and RNA-dependent DNA polymerase. All of these lymphoid line cells had Tac antigen, interleukin-2 receptor, and those of chimpanzee and red-faced macaque had helper/induced T-cell markers, while those derived from African green monkey had suppressor/cytotoxic T-cell markers. Furthermore, simian HTLV-related viruses of pig-tailed macaque, red-faced macaque and Japanese monkey were transmitted to human lymphocytes on co-cultivation.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2579038     DOI: 10.1002/ijc.2910350314

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Human proviral mRNAs down regulated in choriocarcinoma encode a zinc finger protein related to Krüppel.

Authors:  N Kato; K Shimotohno; D VanLeeuwen; M Cohen
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

2.  Enhanced responsiveness to nuclear factor kappa B contributes to the unique phenotype of simian immunodeficiency virus variant SIVsmmPBj14.

Authors:  S C Dollard; S Gummuluru; S Tsang; P N Fultz; S Dewhurst
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

3.  cis-Acting inhibitory elements within the pol-env region of human T-cell leukemia virus type 1 possibly involved in viral persistence.

Authors:  A Saiga; S Orita; N Minoura-Tada; M Maeda; Y Aono; M Asakawa; K Nakahara; R Kubota; M Osame; H Igarashi
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Phylogenetic subtypes of human T-lymphotropic virus type I and their relations to the anthropological background.

Authors:  T Miura; T Fukunaga; T Igarashi; M Yamashita; E Ido; S Funahashi; T Ishida; K Washio; S Ueda; K Hashimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

5.  Identification of novel singly spliced pX mRNA transcripts common to all human T-cell leukemia virus type 1-related retroviruses.

Authors:  S Orita; S Sato; Y Aono; N Minoura; T Yamashita; Y Hinuma; H Igarashi
Journal:  Virus Genes       Date:  1993-06       Impact factor: 2.332

6.  Close association between interleukin 2 receptor mRNA expression and human T cell leukemia/lymphoma virus type I viral RNA expression in short-term cultured leukemic cells from adult T cell leukemia patients.

Authors:  H Umadome; T Uchiyama; T Hori; S Tamori; T Motoi; K Araki; H Uchino
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

7.  Immune recognition of genetically diverse simian T-cell lymphotropic virus type I isolates.

Authors:  A Lazo; R T Bailer; J R Blakeslee; R Yanagihara; V C Stevens; L Kramer; M D Lairmore
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

8.  Heterogeneity of antigen molecules recognized by anti-tax1 monoclonal antibody Lt-4 in cell lines bearing human T cell leukemia virus type I and related retroviruses.

Authors:  Y Tanaka; A Yoshida; Y Takayama; H Tsujimoto; A Tsujimoto; M Hayami; H Tozawa
Journal:  Jpn J Cancer Res       Date:  1990-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.